Study of Ranolazine to Protect Small Heart Vessels in Adults With ST-Elevation Heart Attack and Multiple Blocked Arteries
Led by Federico II University · Updated on 2026-03-11
100
Participants Needed
3
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effect of inhibiting late INa current with ranolazine to improve coronary microcirculation in patients who have acute myocardial infarction heart attack with multivessel disease. This Phase IIb open-label study aims to compare ranolazine plus standard therapy against standard therapy alone in preserving coronary microcirculation after successful primary percutaneous coronary intervention pPCI. The study also investigates various secondary outcomes such as coronary microvascular dysfunction CMD, infarct size, endothelial function, major cardiovascular events, angina symptoms, and quality of life.
Participants will be randomly assigned to one of two groups the experimental group will receive oral ranolazine starting at 500 mg twice daily, increased to 750 mg twice daily from 7 days after pPCI to up to 6 weeks the control group will receive standard therapy without ranolazine. Coronary microcirculation will be assessed invasively or by angiography-based Index of Microcirculatory Resistance IMRangioIMR at baseline after pPCI and at follow-up during staged PCI of non-culprit lesions, either within 5 days or up to 6 weeks. The study is conducted at multiple centers and follows patients for up to 8 weeks.
Participants will undergo coronary microcirculation measurements at two time points along with cardiac magnetic resonance imaging to assess infarct size. Additional assessments include evaluations of endothelial function using EndoPAT, angina symptoms through SAQ7, and quality of life using EuroQoL questionnaires. The study monitors major adverse cardiovascular events MACE, periprocedural myocardial infarction, and other clinical outcomes. The total participation duration lasts approximately 6 to 8 weeks after initial pPCI with close clinical follow-up during this period.
CONDITIONS
Brief Title
Inhibition of Late Sodium Current (INa) to Prevent Coronary MICROvascular Dysfunction in Patients Presenting With ST-Elevation Myocardial Infarction and Multivessel Disease: INaMICRON Study
Research Team
L
Luigi Di Serafino, Professor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Age 18 years or older and less than 80 years at consent
Ability to provide written informed consent within 1 day after successful primary percutaneous coronary intervention (pPCI)
Diagnosis of ST-Elevation Myocardial Infarction (STEMI) during current hospitalization
Successful pPCI with TIMI flow 3 and residual coronary stenosis less than 30%
At least one remaining significant coronary artery stenosis over 50% suitable for PCI
Post-menopausal status or negative pregnancy test for women of child-bearing potential
Agreement to use contraception if sexually active and of child-bearing potential
You will not qualify if you...
Hemodynamically unstable patients
Previous myocardial infarction
Previous coronary artery bypass graft surgery (CABG)
Female patients with positive pregnancy test at enrollment or prior to study drug administration
Pregnant or breastfeeding females or those unwilling to use effective birth control from screening to 90 days after last ranolazine dose
Known allergy to ranolazine or any ingredients
Chronic Kidney Disease stage 4 or 5 (eGFR less than 30 mL/min/1.73 m2)
Moderate to severe liver failure (Child Pugh B or C)
Concurrent use of strong CYP3A4 inhibitors, certain HIV protease inhibitors, class Ia and most class III antiarrhythmic drugs except amiodarone
Participation in another investigational drug trial within 30 days or within 5 half-lives of that drug, whichever is longer
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 6 ± 2 weeks
Participants receive ranolazine by oral administration on top of regular therapy, starting with a dosage of 500mg twice daily and increased to 750mg twice daily from day 7 after successful primary PCI, continuing up to 6 ± 2 weeks. Control group participants receive regular therapy only.
1 baseline visit after successful primary PCI and 1 follow-up visit during staged PCI procedure
Follow-up
Duration - Up to 8 weeks
Participants are monitored for preservation of coronary microcirculation, incidence of major cardiovascular events, angina symptoms, quality of life, and endothelial function up to 8 weeks after treatment.
Approximately 2 visits including assessments at baseline and staged PCI
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Study of Ticagrelor Alone Compared to Ticagrelor Plus Aspirin in Adults With Medically Treated Myocardial Infarction
Comparing Drug Coated Balloon and Drug Eluting Stent in Young Adults Under 50 with STEMI
A Randomized Trial at NICVD Karachi to Improve Heart Attack Treatment
Study of Ranolazine to Protect Small Heart Vessels in Adults With ST-Elevation Heart Attack and Multiple Blocked Arteries
Randomized, Double-Blind Study of Xolatryp Infusion in Adults With STEMI Undergoing Primary PCI to Prevent Reperfusion Injury
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).